Candesartan
Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
---|---|---|---|
Angiotensin II Receptor Blockers | Candesartan | 4-32mg PO Q24H | Administer Anytime During HD; Post HD if Hypotensive |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
---|---|---|---|---|---|---|---|
440 | 52 | 9-13 | 7.3-12 | 99 | 0.13 | N/A | 0 (high flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00796
- Inrig J. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis. 2010;23(3):290-7.
- Ottosson P, Attman P-O, Agren A-C, Samuelsson O. Candesartan cilexetil in haemodialysis patients. Clinical drug investigation. 2003;23(8):545-50.
- Schulz E, Bahri S, Schettler V, Popov A-frederik, Hermann M. Pharmacokinetics and Antihypertensive Effects of Candesartan Cilexetil in Patients Undergoing Haemodialysis. Clinical drug investigation. 2009;29(11):713-719.